BioCentury | Jan 31, 2011
Emerging Company Profile

Medella: RAMPing up

While adrenomedullin has been implicated in the progression of cancer, it was abandoned by pharma years ago due to safety problems stemming from a poor understanding of the target's biology. Medella Therapeutics Ltd. believes it...
Items per page:
1 - 1 of 1